心房颤动与达格列净在射血分数保留或轻度降低患者中的疗效
DELIVER 试验纳入 6,263 例 NYHA II-IV 级、左心室射血分数>40%、有结构性心脏病证据且 NT-proBNP 升高的心力衰竭患者,随机接受达格列净或安慰剂。基线有房颤数据者中 43.3% 无房颤、18.0% 为阵发性房颤、38.7% 为持续性/永久性房颤;达格列净对主要终点(心血管死亡或心衰恶化)的获益在各房颤类型间一致(Pinteraction=0.49)。
要点
- 房颤患者主要终点风险更高,主要由心衰住院率升高驱动。
- 达格列净获益在无房颤、阵发性及持续性/永久性房颤间一致。
- 心衰住院、心血管死亡、全因死亡及 KCCQ-TSS 改善在各房颤类型间效果一致。
核心结论
- 在 DELIVER 中,达格列净相较安慰剂对临床事件和症状的获益不受基线房颤类型影响。
研究设计与样本
- DELIVER 试验(NCT03619213)随机对照研究,共 6,263 例 NYHA II-IV 级、左心室射血分数>40%、有结构性心脏病证据且 NT-proBNP 升高的心衰患者,随机接受达格列净或安慰剂。
- 基线房颤数据可分析的 6,261 例中,43.3% 无房颤、18.0% 为阵发性房颤、38.7% 为持续性/永久性房颤。
主要发现
- 主要终点风险在房颤患者中更高,尤其阵发性房颤,由心衰住院率升高驱动:无房颤每 100 人年 4.5(95%CI: 4.0-5.1),阵发性房颤 7.5(95%CI: 6.4-8.7),持续性/永久性房颤 6.4(95%CI: 5.7-7.1)(P<0.001)。
- 达格列净对主要终点的获益在各房颤类型间一致:无房颤 HR 0.89(95%CI: 0.74-1.08);阵发性房颤 HR 0.75(95%CI: 0.58-0.97);持续性/永久性房颤 HR 0.79(95%CI: 0.66-0.95)(Pinteraction=0.49)。
- 心衰住院、心血管死亡、全因死亡及 KCCQ-TSS 改善在各房颤类型间效果一致。
关键数值与推荐
- 主要终点为心血管死亡或心衰恶化的复合终点。
- 主要终点风险的组间交互作用 Pinteraction=0.49,提示各房颤类型间达格列净获益一致。
临床怎么用
- 对射血分数保留或轻度降低的心衰患者,无论基线房颤类型如何,均可考虑使用达格列净以降低心血管事件风险并改善症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atrial fibrillation (AF) is common in heart failure (HF), is associated with worse outcomes compared with sinus rhythm, and may modify the effects of therapy. OBJECTIVES: This study examined the effects of dapagliflozin according to the presence or not of AF in the DELIVER (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure) trial. METHODS: A total of 6,263 patients with HF with New York Heart Association functional class II-IV, left ventricular ejection fraction >40%, evidence of structural heart disease, and elevated N-terminal pro-B-type natriuretic peptide levels were randomized to dapagliflozin or placebo. Clinical outcomes and the effect of dapagliflozin, according to AF status, were examined. The primary outcome was a composite of cardiovascular death or worsening HF. RESULTS: Of the 6,261 patients with data on baseline AF, 43.3% had no AF, 18.0% had paroxysmal AF, and 38.7% had persistent/permanent AF. The risk of the primary endpoint was higher in patients with AF, especially paroxysmal AF, driven by a higher rate of HF hospitalization: no AF, HF hospitalization rate per 100 person-years (4.5 [95% CI: 4.0-5.1]), paroxysmal AF (7.5 [95% CI: 6.4-8.7]), and persistent/permanent AF (6.4 [95% CI: 5.7-7.1]) (P < 0.001). The benefit of dapagliflozin on the primary outcome was consistent across AF types: no AF, HR: 0.89 (95% CI: 0.74-1.08); paroxysmal AF, HR: 0.75 (95% CI: 0.58-0.97); persistent/permanent AF, HR: 0.79 (95% CI: 0.66-0.95) (Pinteraction = 0.49). Consistent effects were observed for HF hospitalization, cardiovascular death, all-cause mortality, and improvement in the KCCQ-TSS. CONCLUSIONS: In DELIVER, the beneficial effects of dapagliflozin compared with placebo on clinical events and symptoms were consistent, irrespective of type of AF at baseline. (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. [DELIVER]; NCT03619213).
引用
- Butt JH, Kondo T, Jhund PS, et al. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction. J Am Coll Cardiol. 2022. PMID: 36041668. doi:10.1016/j.jacc.2022.08.718
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。